1Gupta, P.; Singh, A.; Rana, S. Interaction of Phosphorylated C5aR1 with β-Arrestin1: A Comparative Structural Modeling Study. 2024 (Under review)
2Singh, A.; Shadangi, S.; Gupta, P.; Rana, S. Type II Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies. 2024 (Under review)
3Ghosh, M; Gupta, P. K.; Jena, S.; Rana, S. The Interaction of Methotrexate with the Human C5a and its Potential Therapeutic Implications. Comput. Biol. Chem. 2024, doi: https://doi.org/10.1016/j.compbiolchem.2024.108283.
4Ghosh, M; Gupta, P. K.; Behera, L. M.; Rana, S. Structure of Designer Antibody-like Peptides Binding to the Human C5a with Potential to Modulate the C5a Receptor Signaling. J. Med. Chem. 2024, 67:14110-14124.
5Behera, L. M.; Gupta, P. K.; Ghosh, M; Shadangi, S; Rana, S. A Rationally Designed Synthetic Antiviral Peptide Binder Targeting the Receptor Binding Domain of SARS-CoV2. J. Phy. Chem. B. 2024, 128(19):4631-4645.
6Gupta, P.; Singh, A.; Rana, S. Conformational variants of the Ternary complex of C5a, C5aR1, and G-protein. J. Bimol. Struct. Dyn. 2024, DOI: 10.1080/07391102.2024.2305698
7Ghosh, M.; Shadangi, S.; Rana, S. Rational Design of Antibody-like Peptides for Targeting the Human Complement Fragment Protein C5a. Proteins, 2024; 92(4):449-463.
8Behera, L. M.; Ghosh, M; Gupta, P. K.; Rana, S. A Rationally Engineered Small Antimicrobial Peptide with Potent Antibacterial Activity. J. Cell. Biochem. 2024, 125(2):e30503
9Gupta, P.; Das, A.; Singh, A.; Rana, S. Ternary Model Structural Complex of C5a, C5aR2, and Beta-Arrestin1. J. Bimol. Struct. Dyn. 2023, http://dx.doi.org/10.1080/07391102.2023.2239927.
10Ghosh, M.; Rana, S. The anaphylatoxin C5a: Structure, Function, Signaling, Physiology, Disease, and Therapeutics. Int. Immunopharmacol. 2023, 118, 110081.
11Das, A.; Ghosh, M.; Gupta, P.; Rana, S. Neutraligands of C5a can Potentially Occlude the Interaction of C5a with the Complement Receptors C5aR1 and C5aR2. J. Cell. Biochem. 2023, 124 (2), 266-281.
12Das, A.; Gupta, P.; Rana, S. C5aR2 Receptor: The Genomic Twin of the Flamboyant C5aR1. J. Cell. Biochem. 2022, 123(11), 1841-1856.
13Behera, L. M.; Ghosh, M.; Rana, S. Deciphering the Conformational Landscape of Few Selected Aromatic Non-Coded Amino acids (NCAAs) for Applications in Rational Design of Peptide Therapeutics. Amino Acids, 2022, 54, 1183-1202.
14Das, A.; Behera, L. M.; Rana, S. "Interaction of Human C5a with the Major Peptide Fragments of C5aR1: Direct Evidence in Support of a "Two-Site" Binding Paradigm". ACS Omega, 2021, 6(35): 22876-22887.
15Das, A.; Rana, S. The Role of Human C5a as a Non-genomic Target in Corticosteroid Therapy for Management of severe COVID19. Comput. Biol. Chem. 2021, 92, 107482.
16Mishra, R.; Behera, L. M.; Rana, S. "Binding of Raloxifene to Human Complement fragment 5a (hC5a): A Perspective on Cytokine Storm and COVID19". J. Bimol. Struct. Dyn. 2020, 15, 1-13.
17Mishra, R.; Das, A.; Rana, S. "Resveratrol Binding to Human Complement fragment 5a (hC5a) may Modulate the C5aR Signaling". J. Bimol. Struct. Dyn. 2020, 17, 1-15.
18Mishra, R.; Rana, S. "A Rational Search for Discovering Potential Neutraligands of Human Complement fragment 5a (hC5a)." Bioorg. Med. Chem. 2019, 27, 115052
19Sahoo, A.; Mishra, R.; Rana, S. "The Model Structures of the Complement Component 5a Receptor (C5aR) Bound to the Native and Engineered hC5a." Sci. Rep. 2018, 8, 2955.
20Rana, S.; Sahoo, A.; Majhi, B. "Structural Complexes of Agonist, Inverse Agonist and Antagonist Bound C5a Receptor: Insights into Pharmacology and Signaling." Mol. BioSyst. 2016, 12, 1586-1599.
21Rana, S.; Sahoo, A.; Majhi, B. "Allosterism in human Complement Component 5a (hC5a): A Damper of C5a Receptor (C5aR) Signaling." J. Bimol. Struct. Dyn. 2015, 1-13.
22Rana, S.; Sahoo, A. "Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation." Biochem. Biophy. Rep. 2015, 1, 85-96.
23Kumar SS; Rana S; Nangia A. "Solid-state form screen of cardiosulfa and its analogues". Chem Asian J. 2013, 8, 1551-68.
24Akiri, K.; Cherukuvada, S.; Rana, S.; Nangia, A."Crystal Structures of Pyridine Sulfonamides and Sulfonic Acids." Cryst. Growth Des. 2012, 12, 4567-73.
25Rana, S.; Yang, L; Hassanian, S. M.; Rezaie A. R. "Determinants of the Specificity of Protease-activated Receptors-1 and 2 Signaling by Factor Xa and Thrombin." J. Cell. Biochem. 2012, 113, 977-84.
26Rana, S.; Baranski, T. J. "Third Extracellular Loop (EC3)-N terminus Interaction is Important for 7TM Receptor Function: Implication for an Activation 'Microswitch' Switch Region." J. Biol. Chem. 2010, 285, 31472-83.
27Rana, S.; Kundu, B.; Durani, S. "A Synthetic Cholinergic Receptor of Mixed-L, D Residues Exceptionally Small and Simple." Biopolymers 2007, 87, 231-243.
28Rana, S.; Kundu, B.; Durani, S. "A Double Catgrip Mixed L and D Mini Protein Only 20 Residues Long." Bioorg. Med. Chem. 2007, 15, 3874-3882.
29Joshi, S.; Rana, S.; Wangikar, P.; Durani, S. "Computational Design of Proteins Stereochemically Optimized in Size, Stability and Folding Speed". Biopolymers 2006, 83, 122-134. (Designed THBs were Featured on the Cover Page of Biopolymers).
30Rana, S.; Kundu, B.; Durani, S. "A Small Peptide Stereochemically Customized as a Globular Fold with a Molecular Cleft". Chemical Communications 2005, 11, 207-209. (Featured as Hot article by Royal Society of Chemistry and as news in Chem. Sci. and Chemistry World, Dec 26, 2004)
31Rana, S.; Kundu, B.; Durani, S. "Stereospecific Peptide Folds. A Rationally Designed Molecular Bracelet." Chemical Communications 2004, 21, 2462-2463.
